MedWatch

Novo and Lundbeck have reduced R&D intensity

While a number of international companies in the past five years have reinvested an increasingly larger part of their revenue in R&D, the opposite trend is evident at two of Denmarks largest pharmaceutical companies. But new strategies may change this fact in the coming years.

Foto: Novo Nordisk / PR

The world’s largest pharmaceutical companies collectively spend an increasingly larger part of their revenue on research and development (R&D), but the opposite development can be traced for the two largest pharmaceutical companies in Denmark, measured by revenue.

A review by MedWatch based on the companies’ financial statements thus shows that both Novo Nordisk and Lundbeck has reduced the so-called R&D intensity during the past 10 years.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier